<DOC>
	<DOCNO>NCT02352753</DOCNO>
	<brief_summary>This prospective , multicenter , single-arm study child 2 17 year age OI evaluate efficacy safety denosumab .</brief_summary>
	<brief_title>Multicenter , Single-arm Study Evaluate Efficacy , Safety , &amp; Pharmacokinetics Denosumab Children w/ OI</brief_title>
	<detailed_description>To evaluate effect denosumab lumbar spine bone mineral density ( BMD ) Z-score 12 month , assess dual-energy X-ray absorptiometry ( DXA ) , inchildren 2 17 year age osteogenesis imperfecta .</detailed_description>
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Clinical diagnosis OI define clinical history consistent type IIV OI Clinical severity OI define 2 prevalent vertebral compression fracture ; OR1 prevalent vertebral compression fracture 1 nonvertebral fracture within previous 2 year ; OR 3 fracture within previous 2 year . Inability unwillingness comply requirement frequent calcium phosphorus monitor 14 day first dose denosumab ( applies first 5 subject age 11 to17 enrol study first 5 subject age meeting criterion increase bone turnover Currently unhealed fracture osteotomy define orthopedic opinion Osteotomy within 5 month screen Evidence untreated oral cavity oral infection Recent plan invasive dental procedure Surgical tooth extraction heal screen History electrophoresis pattern inconsistent type I IV OI History genetic testing result inconsistent type I IV OI Abnormalities follow per central laboratory reference range screen : Serum albumin correct calcium &lt; low limit normal ( LLN ) Serum vitamin D &lt; 20 ng/mL ; rescreening Vitamin D level &lt; 20 ng/mL allow , adequate supplementation Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &gt; 1.5 x upper limit normal ( ULN ) Total bilirubin ( TBL ) &gt; 1.5 x ULN ( subject Gilbert syndrome eligible ) Serum phosphorus &lt; LLN Serum alkaline phosphatase &gt; 20 % ULN &gt; 20 % LLN Estimated glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m2 ( calculate bythe Schwartz equation screen ) Evidence follow : Current hyperthyroidism ( unless wellcontrolled stable antithyroid therapy ) Current clinical hypothyroidism ( unless wellcontrolled stable thyroid replacement therapy ) History hyperparathyroidism Current hypoparathyroidism Current , uncontrolled hypercalcemia ( albumincorrected serum Ca &gt; 10 % ULN ) History osteomalacia rickets ( chart review ) Other bone disease affect bone metabolism ( eg , osteoporosis pseudoglioma syndrome , idiopathic juvenile osteoporosis , osteopetrosis , hypophosphatasia ) History autoimmune disease History rare hereditary problem fructose intolerance Positive blood screen human immunodeficiency virus 1 2 antibody Positive blood screen hepatitis B surface antigen hepatitis C antibody Received osteoporosis treatment bone active treatment follow guideline : Prior treatment § denosumab § fluoride strontium bone disease § parathyroid hormone ( PTH ) PTH derivative within 12 month prior screen § zoledronic acid within 6 month prior screen § oral bisphosphonates intravenous bisphosphonates zoledronic acid first dose denosumab would next scheduled bisphosphonate dose would give Administration systemic glucocorticoid ( ≥ 5.0 mg prednisone equivalents/day 10 day ) within 3 month screen . Topical inhale glucocorticoid allow Administration follow treatment within 3 month screen : § Growth hormone ( subject stable dose growth hormone least 3 month prior screen allow ) Currently receive treatment another investigational drug study , less 30 day since end treatment another investigational drugstudy ( ) , current plan participation clinical trial would preclude compliance study requirement Other inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Amgen , OI , Bone</keyword>
</DOC>